Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving LDRT
Launched by UNIVERSITY OF ERLANGEN-NÜRNBERG MEDICAL SCHOOL · Jan 8, 2016
Trial Information
Current as of June 17, 2025
Recruiting
Keywords
ClinConnect Summary
The IMMO-LDRT01 clinical trial is studying how low dose radiation therapy (LDRT) can help patients with chronic joint diseases, such as painful shoulder or elbow conditions, arthritis, and other related issues. Many patients with these ongoing pain problems do not find relief from standard treatments, and this study aims to explore how LDRT can reduce pain and improve mobility and quality of life. Researchers will analyze the immune system of participants before, during, and after the treatment to better understand how LDRT affects inflammation in the body.
To be eligible for this trial, participants must be at least 18 years old and have a diagnosed chronic joint condition that requires LDRT. Those with a history of cancer, severe substance abuse, or who cannot follow the study rules are not eligible. Participants can expect to receive standard LDRT treatment while allowing researchers to collect information about their immune responses. This study is observational, meaning it won’t change any current treatments but will help improve understanding of how LDRT works in the body.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients suffering and diagnosed for:
- • painful shoulder syndrome (periarthritis humeroscapularis)
- • painful elbow syndrome (Epicondylopathia humeri)
- • benign achillodynia
- • benign calcaneodynia
- • arthosis (finger- , rhiz-, gon-, and anklearthrosis
- • arthritis (gon- and anklearthrosis)
- • Planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
- • Age at least 18 years
- Exclusion Criteria:
- • patients who are suffering or had suffered from any malignant diseases
- • fertile patients who refuse effective contraception during study treatment
- • persistent drug and/or alcohol abuse
- • patients not able or willing to behave according to study protocol
- • patients in care
- • patients that are not able to speak German
About University Of Erlangen Nürnberg Medical School
The University of Erlangen-Nürnberg Medical School is a prestigious institution dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. Renowned for its interdisciplinary approach, the medical school fosters collaboration among experts in various fields, enabling the development of cutting-edge therapies and treatment protocols. With a commitment to ethical standards and patient safety, the institution actively contributes to the global medical community by conducting rigorous clinical studies aimed at enhancing the understanding and management of diverse health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erlangen, Bavaria, Germany
Patients applied
Trial Officials
Oliver J Ott, MD
Principal Investigator
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
Udo S Gaipl, PhD
Principal Investigator
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials